Zhang Pei-Lan, Wang Yu-Xin, Chen Yan, Zhang Chen-Hao, Li Chen-Hua
Department of Neurology, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China.
Exp Ther Med. 2018 Jan;15(1):127-130. doi: 10.3892/etm.2017.5377. Epub 2017 Oct 26.
The aim of the study was to investigate the efficacy of homemade tolcapone in treatment of patients with Parkinson's disease (PD). Eighty patients with PD were subjected to randomized, double-blind, placebo-controlled and parallel-group study. PD patients were randomly divided into the tolcapone treatment group (41 cases) and placebo group (39 cases). Each patient received 1 pill of tolcapone or placebo, 3 times per day for 26 weeks. Efficacy was evaluated using the internationally used unified Parkinson's disease rating scale (UPDRS) scoring system for PD symptoms. After the treatment for 26 weeks, the cognitive function, tremor, muscle stiffness, voluntary movement and autonomic nerve symptoms were compared between the two groups using UPDRS scores. Compared with the placebo group, cognitive function, muscle stiffness and voluntary movement reduction were significantly improved in patients of the tolcapone group (P<0.05). However, no significant differences in UPDRS scores of autonomic nerve symptoms and tremor were found between two groups after treatment (P>0.05). Tolcapone, a catechol--methyl transferase (COMT) inhibitor, can improve the motor function of patients with PD, especially exercise and muscle stiffness. Tolcapone can also improve the cognitive function of patients.
本研究的目的是探讨自制托卡朋治疗帕金森病(PD)患者的疗效。80例PD患者进行随机、双盲、安慰剂对照和平行组研究。将PD患者随机分为托卡朋治疗组(41例)和安慰剂组(39例)。每位患者服用1片托卡朋或安慰剂,每日3次,共26周。采用国际通用的帕金森病统一评分量表(UPDRS)评分系统对PD症状进行疗效评估。治疗26周后,用UPDRS评分比较两组患者的认知功能、震颤、肌肉僵硬、自主运动及自主神经症状。与安慰剂组相比,托卡朋组患者的认知功能、肌肉僵硬及自主运动减退明显改善(P<0.05)。然而,治疗后两组自主神经症状和震颤的UPDRS评分差异无统计学意义(P>0.05)。托卡朋作为一种儿茶酚-O-甲基转移酶(COMT)抑制剂,可改善PD患者的运动功能,尤其是运动和肌肉僵硬。托卡朋还可改善患者的认知功能。